[2-[2-(methylamino)acetyl]oxy-5-[(2S)-2-[1-(2-methylpropanoyloxy)ethoxycarbonylamino]-3-oxo-3-propan-2-yloxypropyl]phenyl] benzoate

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 缩酚酸和缩酚酸环醚类
• 英文名称: [2-[2-(methylamino)acetyl]oxy-5-[(2S)-2-[1-(2-methylpropanoyloxy)ethoxycarbonylamino]-3-oxo-3-propan-2-yloxypropyl]phenyl] benzoate
• 化学式: C₂₉H₃₆N₂O₁₀
• 分子量: 572.6
• InChiKey: CYXWSZDGGUAXAB-BPARTEKVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  41
• 可旋转键数：
  18
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.41
• 拓扑面积：
  156
• 氢给体数：
  2
• 氢受体数：
  11

文献信息

• [EN] NOVEL HIGH PENETRATION DRUGS AND THEIR COMPOSITIONS THEREOF FOR TREATMENT OF PARKINSON DISEASES<br/>[FR] NOUVEAUX MÉDICAMENTS À PÉNÉTRATION ÉLEVÉE ET LEURS COMPOSITIONS POUR LE TRAITEMENT DE MALADIES DE PARKINSON
  申请人：TECHFIELDS PHARMA CO LTD

  公开号：WO2014139161A1

  公开（公告）日：2014-09-18

  One aspect of the invention provides a composition of novel high penetration compositions (HPC) or a high penetration prodrug (HPP) for treatment of Parkinson's disease. The HPCs/HPPs are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, the HPPs are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPCs/HPPs can be administered to a subject through various administration routes, e.g., locally delivered to an action site of a condition with a high concentration or systematically administered to a biological subject and enter the general circulation with a faster rate.

  本发明的方面之一提供了用于治疗帕金森病的新型高渗透组合物（HPC）或高渗透前药（HPP）。HPCs/HPPs能够穿过生物屏障后转化为母药活性药物或药物代谢物，因此能够对母药或代谢物能够治疗的疾病进行治疗。此外，HPPs能够到达母药可能无法进入的区域或在目标区域达到足够的浓度，从而实现新的治疗方法。HPCs/HPPs可以通过各种给药途径给药给受试者，例如，局部施用于具有高浓度的疾病作用部位，或者系统性地给药给生物受试者，并以更快的速率进入全身循环。
• High penetration drugs and their compositions thereof for treatment of Parkinson diseases
  申请人：Techfields Pharma Co., Ltd.

  公开号：US11084813B2

  公开（公告）日：2021-08-10

  One aspect of the invention provides a composition of novel high penetration compositions (HPC) or a high penetration prodrug (HPP) for treatment of Parkinson's disease. The HPCs/HPPs are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, the HPPs are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPCs/HPPs can be administered to a subject through various administration routes, e.g., locally delivered to an action site of a condition with a high concentration or systematically administered to a biological subject and enter the general circulation with a faster rate.

  本发明的一个方面提供了一种用于治疗帕金森病的新型高渗透组合物（HPC）或高渗透原药（HPP）。HPCs/HPPs 在穿过生物屏障后能够转化为母体活性药物或药物代谢物，因此能够对母体药物或代谢物所能治疗的病症进行治疗。此外，HPPs 还能到达母体药物可能无法到达的区域，或在目标区域产生足够的浓度，从而提供新的治疗方法。HPCs/HPPs 可通过各种给药途径给受试者用药，例如，以高浓度局部给药到疾病的作用部位，或系统地给生物受试者用药，并以更快的速度进入血液循环。
• NOVEL HIGH PENETRATION DRUGS AND THEIR COMPOSITIONS THEREOF FOR TREATMENT OF PARKINSON DISEASES
  申请人：Techfields Pharma Co., Ltd.

  公开号：US20170334908A1

  公开（公告）日：2017-11-23

  One aspect of the invention provides a composition of novel high penetration compositions (HPC) or a high penetration prodrug (HPP) for treatment of Parkinson's disease. The HPCs/HPPs are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, the HPPs are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPCs/HPPs can be administered to a subject through various administration routes, e.g., locally delivered to an action site of a condition with a high concentration or systematically administered to a biological subject and enter the general circulation with a faster rate.
• US9718766B2
  申请人：——

  公开号：US9718766B2

  公开（公告）日：2017-08-01